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1 
METHOD FOR CONTROLLING CELL 
NECROSIS OR APOPTOSIS 
RELATED APPLICATIONS 
This application is a continuation in part of application 
Ser. No. 09/452,617, ?led Dec. 1, 1999, now US. Pat. No. 
6,337,065, Which claims priority provisional patent appli 
cation serial No. 60/110,482, ?led Dec. 1, 1998. Both 
applications are incorporated by reference in their entirety. 
BACKGROUND 
1. Field of the Invention 
The invention is directed to methods and composition of 
using organic molecules termed pro-NAD agents, capable of 
enhancing dermal and epidermal skin cell NAD content With 
a resulting enhancement of DNA repair and other protective 
responses to genotoxic stress in skin. Also a part of the 
invention are methods for manipulating cell regulation path 
Ways involving NAD via, e.g., enhancement or inhibition of 
enZymatic pathWays. 
2. Description of the Background 
The present application relates to methods and composi 
tions capable of modulating and upregulating the cellular 
nicotinamide-adenine-dinucleotide (NAD) content by the 
topical application of chemical agents for the purpose of 
enhancing natural protective responses of skin cells to DNA 
damage. Also a part of the invention is the manipulation of 
enZymatic pathWays associated thereWith. The methods and 
compositions are effective, e.g., for the prevention and 
treatment of skin deterioration that results from DNA dam 
age to cells of the skin, as Well as in the treatment of other 
conditions Which involve enZymatic pathWays Where NAD 
is a substrate. The symptoms of such skin deterioration are 
many and typically include the loss of moisture, ?ne lines, 
deep lines, Wrinkles, and loss of elasticity as Well as atrophic 
sclerosis and other blemishes of skin. Skin deteriorates With 
age as a natural consequence of prolonged exposure to 
internal and external factors. Internal deterioration factors 
include natural metabolic byproducts such as free radicals 
Which cause the aging of all tissues. External deterioration 
factors include ioniZing radiation such as sunlight and 
chemical insults such as pollution and cigarette smoke. In 
theory, skin care methods and compositions should inhibit, 
or sloW the process of skin deterioration by counteracting 
these internal and external factors. Unfortunately, current 
methods and compositions for skin care are generally reac 
tive rather than proactive. That is, current methods and 
compositions reduce or obscure the signs of aging but have 
minimal or no effect on the underlying progressive and 
cumulative biochemical processes that cause skin deterio 
ration. It is therefore desirable to have a skin care method 
and composition Which not only reduce the symptoms of 
deterioration but also treat the underlying causes of skin 
deterioration in such a Way that deterioration can actually be 
retarded. To understand the limitations of current methods 
and compositions, it is necessary to understand the function 
and structure of the skin and the mechanisms of skin 
deterioration. 
At ten pounds, the skin is the largest organ in the body. 
FIG. 1 shoWs a diagram of skin marking the location of the 
tWo major cell types present in skin, namely ?broblasts, 
Which are located in the dermal layer of the skin and 
keratinocytes, Which are located in the epidermal layer of the 
skin. The skin provides the ?rst line of defense betWeen the 
body’s interior and harmful environmental insults by Well 
established physical and biochemical mechanisms. Physical 
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protection mechanisms include the relatively impermeable 
barrier the skin provides. The skin can, to some extent, repel 
and absorb insults such as chemicals and ultraviolet light so 
that While the skin may be damaged, the underlying tissue is 
preserved. Biochemical mechanisms include the innate and 
acquired immune systems. Microbiological pathogens are 
repelled by immune responses at the epidermal level involv 
ing Langerhans cells, keratinocytes, cytokines, polynuclear 
cells, endothelial cells, mast cells, and lymphocytes. 
Structurally, the skin comprises epithelial tissue (the 
epidermis) in the outer layer and beneath it, connective 
tissue (the dermis), and beneath that, the fatty tissue 
(hypodermis). The epidermis is not vasculariZed and regen 
erates every four to six Weeks. Its primary function is to 
maintain the body’s skin integrity, acting as a physical 
barrier to toxic agents, dirt, bacteria, microorganisms, and 
physical insults. The dermis is beneath the epidermis and 
functions by providing strength, support, blood, and oxygen 
to the skin. The principal cell components of the dermis are 
?broblasts, although it also contains sWeat glands, sebaceous 
glands, hair follicles, and small fat cells. Hypodermis, also 
knoWn as the super?cial fascia, attaches the dermis to the 
underlaying structures. Its function is to promote an ongoing 
blood supply to the dermis for regeneration. 
The mechanisms of skin deterioration involve a gradual 
and progressive process that begins at birth. Internal factors 
that contribute to skin aging include toxic metabolic 
byproducts, autoimmune diseases, and genetic predisposi 
tion. The consequences of internal deterioration can be 
observed over the entire body from the skin to the internal 
organs. While the mechanisms of internal deterioration are 
not completely understood, somatic mutation has been 
shoWn to be a contributing factor. Under the somatic muta 
tion theory, cells gradually lose their youthful characteristics 
and their capacity to divide by the accumulation of muta 
tions (errors) in their genetic code. These mutations may be 
caused by free radicals or alkylating agents generated in 
metabolism that lead to unrepaired DNA damage. Over time, 
mutations accumulate in the body until the cell can no longer 
divide or produce functional proteins. 
External factors such as chemical and physical agents in 
the environment can also cause DNA damage that leads to 
skin deterioration. The external factors include sunlight, 
pollution, and ingested chemicals from smoking or from 
food. 
Deterioration of skin leads to changes in dermal thickness 
and elasticity due to increased crosslinking of collagen. 
Epidermal regeneration increases in activity While 
metabolism, sWeat glands, and vasculariZation, all decrease 
in activity. The damage from internal and external factors is 
progressive and cumulative and results in the appearance of 
deterioration associated With aged skin. 
Related to the somatic mutation theory, both internal and 
external factors contribute to oxidative stress, Which in turn 
results in DNA damage. In humans, oxidative stress and 
DNA damage is caused by factors such as hyperbaric 
oxygen, gamma radiation, ultraviolet radiation, oZone, 
peroxides, free radicals, alkylating agents, and redox cycling 
drugs. While total oxidative stress and DNA damage may be 
reduced by living in a loW pollution environment and 
avoiding sunlight, they cannot be eliminated. Some factors 
like ioniZing radiation are present in all environments at a 
loW level and other factors are byproducts of metabolism 
and cannot be totally eliminated. Further, urban environ 
ments have high levels of ground level pollution from a 
variety of sources that are not likely to be reduced in the near 













